<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620594</url>
  </required_header>
  <id_info>
    <org_study_id>CBEZ235A2101</org_study_id>
    <secondary_id>2006-004353-23</secondary_id>
    <nct_id>NCT00620594</nct_id>
  </id_info>
  <brief_title>A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer</brief_title>
  <official_title>A Phase I/II, Multi-center, Open-label Study of BEZ235, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This is a first-in-human, phase I/Ib clinical research study with BEZ235, an inhibitor of&#xD;
      phosphatidylinositol 3'-kinase (PI3K). The study consists of a dose escalation part followed&#xD;
      by a safety dose expansion part:&#xD;
&#xD;
      Dose escalation part (advanced solid tumors, including patients with breast cancer being&#xD;
      treated with trastuzumab):&#xD;
&#xD;
      Patients receive oral BEZ235 once daily on days 1-28 of the first course. Courses will repeat&#xD;
      every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of at least 3 patients receive escalating doses of BEZ235, as single agent or in&#xD;
      combination with trastuzumab, until the maximum tolerated dose (MTD) is determined. The MTD&#xD;
      is defined as the dose expected to produce during the first course of treatment dose-limiting&#xD;
      toxicity in 33% of patients.&#xD;
&#xD;
      Once the MTD has been defined, the safety expansion parts of the trial will be opened for&#xD;
      enrollment.&#xD;
&#xD;
      Safety dose expansion part (advanced solid tumors, including patients with breast cancer&#xD;
      being treated with trastuzumab):&#xD;
&#xD;
      Patients will be treated with BEZ235, as single agent or in combination with trastuzumab,&#xD;
      given at the MTD, once daily. Treatment of patients will continue until disease progression&#xD;
      or occurrence of unacceptable side effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 21, 2006</start_date>
  <completion_date type="Actual">January 8, 2013</completion_date>
  <primary_completion_date type="Actual">January 8, 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>determine the maximum Tolerated Dose (MTD) of BEZ235 as single agent and in combination with trastuzumab (Dose escalation part)</measure>
    <time_frame>at end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>assess the safety &amp; tolerability of BEZ235 SDS as single agent and in combination with trastuzumab administered to patients at the MTD level (Safety expansion part)</measure>
    <time_frame>at end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>assess the safety and tolerability of the various formulations of BEZ235</measure>
    <time_frame>at end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asses the Pharmacokinetics of BEZ235 which includes AUC, Cmax, Tmax, t1/2 as endpoints</measure>
    <time_frame>at end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity (tumor response) of BEZ235 SDS as single agent and in combination with trastuzumab</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cowden Syndrome</condition>
  <arm_group>
    <arm_group_label>BEZ235 Alone, Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BEZ235 + trastuzumab, Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BEZ235 Alone, MTD Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BEZ235 + Trastuzumab, MTD Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BEZ235</intervention_name>
    <arm_group_label>BEZ235 + Trastuzumab, MTD Expansion</arm_group_label>
    <arm_group_label>BEZ235 + trastuzumab, Dose Escalation</arm_group_label>
    <arm_group_label>BEZ235 Alone, Dose Escalation</arm_group_label>
    <arm_group_label>BEZ235 Alone, MTD Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        [Single agent dose escalation arm]: Patients with histologically-confirmed, advanced&#xD;
        unresectable solid tumors including CS patients who have progressed on (or not been able to&#xD;
        tolerate) standard therapy within three months before screening visit or for whom no&#xD;
        standard anticancer therapy exists.&#xD;
&#xD;
        [Combination part]: Patients with metastatic HER2+ Breast Cancer, after failure of&#xD;
        trastuzumab treatment. Eligible patients will have to have tumors carrying molecular&#xD;
        alterations of PIK3CA and/or PTEN.&#xD;
&#xD;
        [Single agent safety expansion arm]: Patients with histologically-confirmed, advanced&#xD;
        unresectable solid tumors including CS patients who have progressed on (or not been able to&#xD;
        tolerate) standard therapy within three months before screening visit or for whom no&#xD;
        standard anticancer therapy exists. Patients will be prescreened for molecular alterations&#xD;
        affecting PIK3CA and/or PTEN. Patients with NSCLC will also be pre-screened for EGFR&#xD;
        mutation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have brain metastases, which are progressive and/or requiring medical&#xD;
             intervention for symptom control&#xD;
&#xD;
          -  Prior treatment with a PI3K inhibitor&#xD;
&#xD;
          -  Acute or chronic liver disease or renal disease&#xD;
&#xD;
          -  Acute or chronic pancreatitis&#xD;
&#xD;
          -  Patients with unresolved diarrhea â‰¥ CTCAE grade 2&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac diseases&#xD;
&#xD;
          -  Patients with diabetes mellitus requiring insulin treatment&#xD;
&#xD;
          -  Patients with known coagulopathies&#xD;
&#xD;
          -  Patients with a history of photosensitivity reactions to other drugs&#xD;
&#xD;
          -  Any of the following ophthalmological findings:&#xD;
&#xD;
          -  Progressive eye disease that could lead to severe loss of visual acuity or visual&#xD;
             field&#xD;
&#xD;
          -  loss during the study period&#xD;
&#xD;
          -  Inability to perform the ophthalmic procedures required in this protocol&#xD;
&#xD;
          -  Other concurrent severe and/or uncontrolled concomitant medical conditions (e.g.&#xD;
             active or uncontrolled infection) that could cause unacceptable safety risks or&#xD;
             compromise compliance with the protocol.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at Los Angeles JonssonComprehensiveCancerCtr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine YaleCancerCtr-ClinTrialsOffice</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute Clinical Trials ProjectManager</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Cancer Institute NVCC - Huntsman</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of the Carolinas CCC Faris</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute Dept.ofSarahCannonCancerCtr(2)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Health Care System/Sammons Cancer Center Baylor- Sammons</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center Thoractic Head/Neck Med.Onc(2)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center TCC</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manchester</city>
        <zip>M20 9BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=10543</url>
    <description>Results for CBEZ235A2101 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>February 2017</verification_date>
  <study_first_submitted>February 8, 2008</study_first_submitted>
  <study_first_submitted_qc>February 20, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoplasms</keyword>
  <keyword>breast neoplasms</keyword>
  <keyword>breast diseases</keyword>
  <keyword>solid tumors</keyword>
  <keyword>BEZ235</keyword>
  <keyword>breast cancer</keyword>
  <keyword>PI3K Inhibitor</keyword>
  <keyword>Phosphatidylinositol 3</keyword>
  <keyword>kinase</keyword>
  <keyword>advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hamartoma Syndrome, Multiple</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dactolisib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

